尼达尼布在TOMORROW和INPULSIS试验中按基线心血管风险分层的心血管安全性
该研究汇总TOMORROW和INPULSIS试验数据,事后评估尼达尼布在特发性肺纤维化患者中的心血管安全性。共纳入1231例患者(尼达尼布组723例,安慰剂组508例),其中89.9%为基线心血管风险较高者。结果显示,无论基线心血管风险高低,尼达尼布组与安慰剂组的主要不良心血管事件发生率相似。
要点
- 尼达尼布组与安慰剂组主要不良心血管事件发生率在基线心血管风险较高和较低患者中均相似。
- 基线心血管风险较高患者中,尼达尼布组心肌梗死发生率为3.03/100患者年,安慰剂组为1.16/100患者年。
- 基线心血管风险较低患者中,尼达尼布组其他缺血性心脏病发生率为0,安慰剂组为1.80/100患者年。
核心结论
- 在特发性肺纤维化患者中,尼达尼布组与安慰剂组的主要不良心血管事件发生率在基线心血管风险较高和较低亚组中均相似。
研究设计与样本
- 汇总TOMORROW和INPULSIS试验数据的事后分析,共纳入1231例患者(尼达尼布组723例,安慰剂组508例),其中89.9%为基线心血管风险较高者。
主要发现
- 基线心血管风险较高患者中,尼达尼布组和安慰剂组主要不良心血管事件发生率分别为3.88(95%CI 2.58-5.84)和3.49(95%CI 2.10-5.79)/100患者年。
- 基线心血管风险较低患者中,尼达尼布组和安慰剂组主要不良心血管事件发生率分别为4.78(95%CI 1.54-14.82)和5.37(95%CI 1.73-16.65)/100患者年。
- 基线心血管风险较高患者中,尼达尼布组和安慰剂组心肌梗死发生率分别为3.03(95%CI 1.91-4.81)和1.16(95%CI 0.48-2.79)/100患者年。
- 基线心血管风险较低患者中,尼达尼布组和安慰剂组心肌梗死发生率分别为1.59(95%CI 0.22-11.29)和1.78(95%CI 0.25-12.64)/100患者年。
- 基线心血管风险较高患者中,尼达尼布组和安慰剂组其他缺血性心脏病发生率分别为1.85(95%CI 1.02-3.34)和3.28(95%CI 1.94-5.54)/100患者年。
临床怎么用
- 对于基线心血管风险较高的特发性肺纤维化患者,使用尼达尼布时主要不良心血管事件风险与安慰剂相似,可结合个体情况评估后使用。
局限性
- 该分析为事后分析,基线心血管风险较低亚组样本量较小,置信区间较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nintedanib is a tyrosine kinase inhibitor used to treat idiopathic pulmonary fibrosis (IPF). We investigated the cardiovascular safety of nintedanib using pooled data from the TOMORROW and INPULSIS trials.Cardiovascular events were assessed post hoc in patients with a history of atherosclerotic cardiovascular disease (CVD) and/or one or more cardiovascular risk factors at baseline ("higher cardiovascular risk") and patients with no history of atherosclerotic CVD and no cardiovascular risk factors at baseline ("lower cardiovascular risk").Incidence rates were calculated for 1231 patients (n=723 nintedanib and n=508 placebo), of whom 89.9% had higher cardiovascular risk. Incidence rates of major adverse cardiovascular events were similar in the nintedanib and placebo groups in patients with higher cardiovascular risk (3.88 (95% CI 2.58-5.84) and 3.49 (95% CI 2.10-5.79) per 100 patient-years, respectively) and lower cardiovascular risk (4.78 (95% CI 1.54-14.82) and 5.37 (95% CI 1.73-16.65) per 100 patient-years, respectively). Incidence rates of myocardial infarction in the nintedanib and placebo groups, respectively, were 3.03 (95% CI 1.91-4.81) and 1.16 (95% CI 0.48-2.79) per 100 patient-years in patients with higher cardiovascular risk and 1.59 (95% CI 0.22-11.29) and 1.78 (95% CI 0.25-12.64) per 100 patient-years in patients with lower cardiovascular risk. Incidence rates of other ischaemic heart disease in the nintedanib and placebo groups, respectively, were 1.85 (95% CI 1.02-3.34) and 3.28 (95% CI 1.94-5.54) per 100 patient-years in patients with higher cardiovascular risk and 0 and 1.80 (95% CI 0.25-12.78) per 100 patient-years in patients with lower cardiovascular risk.These data help to establish the cardiovascular safety profile of nintedanib in IPF.
引用
- Noth I, Wijsenbeek M, Kolb M, et al. Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials. Eur Respir J. 2019. PMID: 31285303. doi:10.1183/13993003.01797-2018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。